EXEL - Exelixis Inc

-

$undefined

N/A

(N/A)

Exelixis Inc NasdaqGS:EXEL Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Location: 1851 Harbor Bay Parkway, Alameda, CA, 94502, United States | Website: https://www.exelixis.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

10.77B

Cash

1.031B

Avg Qtr Burn

N/A

Short % of Float

8.06%

Insider Ownership

2.18%

Institutional Own.

94.19%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

COMETRIQ (cabozantinib) Details
Metastatic MTC (Medullary Thyroid Cancer)

Approved

Quarterly sales

CABOMETYX (cabozantinib) Details
Renal cell carcinoma, neuroendocrine tumors (NETs)

Approved

Quarterly sales

CABOMETYX (cabozantinib) + atezolizumab Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

sNDA

Submission

Zanzalintinib Details
Solid tumor/s, Kidney cancer, Renal cell carcinoma

Phase 3

Data readout

Zanzalintinib + atezolizumab Details
Solid tumor/s, Cancer, Metastatic colorectal cancer

Phase 3

Data readout

Zanzalintinib + KEYTRUDA (Pembrolizumab) Details
Cancer, Head and neck squamous cell carcinoma

Phase 3

Data readout

Zanzalintinib Details
Neuroendocrine tumor

Phase 3

Initiation

Zanzalintinib + AB521 Details
Cancer, Kidney cancer, Renal cell carcinoma

Phase 1/2

Update

Zanzalintinib +/- atezolizumab Details
Solid tumor/s, Cancer, Carcinoma

Phase 1/2

Update

Phase 1b

Data readout

CBX-12 Details
Cancer, Solid tumor/s

Failed

Discontinued

Failed

Discontinued

XL495 Details
Solid tumor/s, Cancer

Failed

Discontinued